SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Coming soon · Friday 13 November · 09:45 CET

The International Lung Cancer Summit 2026

Live Summit5 CME credits · EACCME & SSMO

Event details

The International Lung Cancer Summit 2026

Led by global experts

The people in the room

A global roster of oncologists, surgeons and pathologists — chaired from Lausanne, drawn from across the field.

Solange Peters

Chair, Switzerland

Alfredo Addeo

Chair, Switzerland

Umberto Malapelle

Italy

Hidehito Horinouchi

Japan

Telma Sequeira

Portugal

Christine Lovly

USA

David Planchard

France

Sandip Patel

USA

Alessio Cortellini

Italy

Lauren Byers

USA

Giannis Mountzios

Greece

Anne-Marie Dingemans

Netherlands

The programme · 13 Nov 2026

The day, hour by hour

The full running order — every session, its time, and who is giving it.

Morning 09:45 – 12:30
09:45

Welcome & introduction

Peters & Addeo · chairs
09:50

Emerging biomarkers and liquid biopsies

Umberto Malapelle
10:10

New standards in EGFR- and ALK-positive NSCLC

Hidehito Horinouchi
10:35

Other actionable genomic alterations, incl. HER2 and ROS1

Telma Sequeira
11:00Open discussion & coffee break
11:20

Targeting (K)RAS with new compounds

Christine Lovly
11:50

The ADC wave: integrating new agents in NSCLC

David Planchard
12:30Industry satellite symposia
Afternoon 14:15 – 17:00
14:15

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

Sandip Patel
14:40

New compounds and combinations for non-oncogene-addicted advanced NSCLC

Alessio Cortellini
15:10Open discussion & coffee break
15:30

The emerging role of T-cell engagers and ADCs in SCLC

Lauren Byers
16:35

Panel · open questions & patient cases

All speakers & attendees
17:00

Closing remarks

Peters & Addeo · chairs
Industry satellite symposia
12:30

Programme to be announced

13:00

Programme to be announced

Where we meet · Lausanne

On site & online

Hosted at CHUV in Lausanne and live-streamed worldwide — join in person, or from your own clinic.

VenueCHUV · Bâtiment AGORA
AddressRue du Bugnon 25A, 1005 Lausanne
DateFri 13 Nov 2026 · 09:45 CET
FormatHybrid · live-streamed · CME-certified

ILCS · In frames

Last year, in Lausanne

A day on the ground — faculty, debate and the room between sessions.

       Continue With

Related Topics

Charles Rudin
Aug 07 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients

Read the article

C. Rudin
Aug 07 2026
TARGETED THERAPIES
Advanced NSCLCBiomarkersTargeted Therapies

EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R

Read the article

B. Ricciuti
Aug 07 2026
ADCs
Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

Read the article

G. Mountzios
Aug 07 2026
TARGETED THERAPIES
Advanced NSCLCTargeted Therapies

ORCHARD final data: osimertinib plus gefitinib gives modest benefit in EGFR C797X, and the authors advise against further study

Read the article

X. LeZ. Piotrowska
Jul 23 2026
TARGETED THERAPIES
Advanced NSCLCTargeted Therapies

Zidesamtinib approved in the US for previously treated ROS1-positive non-small cell lung cancer

Read the article

Jul 20 2026
ADCs
Advanced NSCLCADCs

Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC

Read the article

Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Jul 15 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC

Read the article

A. CortelliniD. PlanchardJ. NaidooJ. RemonB. Ricciuti
Jul 14 2026
ADCs
Advanced NSCLCADCs

Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date

Read the article

M. HochmairG. MountziosA. AddeoM. Reck
Jul 14 2026
ADCs
Advanced NSCLCSCLCADCs

Antibody-drug conjugates across solid tumours: an ETOP/IBCSG expert group sets the research priorities

Read the article

R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
Jul 13 2026
TARGETED THERAPIES
Advanced NSCLCTargeted Therapies

Roche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLC

Read the article

Jul 11 2026
TARGETED THERAPIES
Resectable NSCLCTargeted Therapies

AstraZeneca reports five-year adjuvant osimertinib follow-up data in early-stage EGFR-mutated NSCLC

Read the article

Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro